Sponsor or institution

Clinical trials and research at Unicancer

• 38Clinical trials
• 15Countries

Newest trials

All recruiting trials (38)

• Skipping hormone therapy for some low-risk early breast cancer patients

  This trial tests whether certain older, postmenopausal women with very small, low-risk ER-positive HER2-negative breast cancers can skip hormone therapy after surgery without raising the chance of cancer coming back.

  Recruiting at 10 sites Phase 2 Unicancer · Angers and 40 other locations · NCT07661927

• Immunotherapy Master Trial for Advanced Cancers

  This trial tests a master protocol called METAREM to see if personalized immunotherapy strategies can help people with advanced or metastatic solid tumors.

  Recruiting Phase 2 Unicancer · Villejuif · NCT07431073

• Immunotherapy without chemotherapy for first-line advanced NSCLC with high PD-L1

  This trial tests pembrolizumab or cemiplimab as first-line treatment for adults with advanced NSCLC and high PD-L1, to see if immunotherapy alone can be effective without chemotherapy.

  Recruiting Phase 2 Unicancer · Bordeaux and 3 other locations · NCT07360743

• Neo‑adjuvant immunotherapy program for localized cancers

  This program tests tailored neo‑adjuvant immunotherapy approaches guided by rapid blood and fresh tumor profiling for people with localized solid cancers who are candidates for preoperative therapy.

  Recruiting Phase 2 Unicancer · Villejuif · NCT07262489

• Finding better ways to detect resistance to antibody‑drug conjugates in solid tumors and identify useful biomarkers

  This trial tests whether tissue and blood biomarkers collected before and after treatment can reveal why antibody‑drug conjugates stop working in adults with advanced breast, gastric, urothelial, or non‑small cell lung cancer.

  Recruiting Phase 2 Unicancer · Villejuif · NCT07259226

• Using ribociclib plus hormone therapy to avoid adjuvant chemotherapy in intermediate-risk HR+/HER2- early breast cancer

  This trial tests whether some women with intermediate-risk hormone receptor–positive, HER2-negative early breast cancer can skip adjuvant chemotherapy and instead receive ribociclib with endocrine therapy.

  Recruiting at 29 sites Phase 3 Unicancer · Amiens and 137 other locations · NCT07237256

• Neoadjuvant intratumoral ipilimumab plus nivolumab for resectable stage III melanoma

  This trial tests whether injecting ipilimumab and nivolumab directly into tumors before surgery helps adults with resectable stage III cutaneous or mucosal melanoma.

  Recruiting at 6 sites Phase 2 Unicancer · Bordeaux and 5 other locations · NCT07230613

• Zanidatamab for solid tumors with HER2 changes

  This study will try zanidatamab, an anti-HER2 drug, in adults with advanced endometrial, colorectal, head and neck, sarcoma, or non-small cell lung cancer whose tumors have specific HER2 changes.

  Recruiting at 2 sites Phase 2 Unicancer · Angers and 3 other locations · NCT07192068

• Using AI to predict and share risk of arm swelling after nodal radiotherapy

  This trial will test whether showing women having lymph‑node radiotherapy after breast cancer surgery their personalized AI-predicted risk of arm swelling helps guide care decisions.

  Recruiting at 27 sites Unicancer · Arras and 26 other locations · NCT07187726

• Online education plus personalized prevention plan for women at high breast cancer risk.

  This project tests an online webinar and a personalized virtual clinical visit to teach women at high 5-year breast cancer risk how to lower their risk through lifestyle changes and a tailored prevention plan.

  Recruiting Unicancer · Lyon and 2 other locations · NCT07120087

• Personalized chemo decisions for young HR+/HER2- breast cancer patients

  This trial tests whether using a genomic test can safely spare some premenopausal patients from chemotherapy in favor of endocrine therapy alone.

  Recruiting at 23 sites Phase 3 Unicancer · Brussels and 104 other locations · NCT07106632

• Durvalumab plus tremelimumab with or without liver-directed GEMOX chemotherapy for hepatocellular carcinoma

  This trial tests whether adding hepatic arterial infusion chemotherapy (GEMOX) to the immunotherapy combination durvalumab plus tremelimumab helps people with hepatocellular carcinoma who have a high tumor burden in the liver.

  Recruiting at 5 sites Phase 2/3 Unicancer · Bordeaux and 10 other locations · NCT06904170

• Ivonescimab plus chemotherapy for advanced or metastatic gastric and gastroesophageal adenocarcinoma

  This trial tests whether adding ivonescimab to standard chemotherapy helps adults with advanced or metastatic gastric or gastroesophageal adenocarcinoma respond better to treatment.

  Recruiting at 2 sites Phase 2 Unicancer · Lyon and 3 other locations · NCT06846346

• Detecting Tumor DNA in Blood to Find T-DXd Candidates in HR+/HER2-Low Metastatic Breast Cancer

  We test whether persistent tumor DNA in blood after starting standard therapy can identify HR+ HER2-low metastatic breast cancer patients who may benefit from trastuzumab deruxtecan.

  Recruiting at 12 sites Phase 2 Unicancer · Amiens and 39 other locations · NCT06680596

• Using Pemigatinib to Treat Solid Tumors with FGFR Gene Alterations

  This study is testing if pemigatinib can help people with solid tumors that have FGFR gene changes, especially those with hard-to-treat cancers.

  Recruiting Phase 2 Unicancer · Brest and 5 other locations · NCT06653777

• Darolutamide with standard or higher-dose targeted prostate radiotherapy plus hormone therapy for men with high-risk localized prostate cancer

  This trial tests whether adding darolutamide and/or using higher-dose targeted prostate radiotherapy together with hormone therapy and pelvic nodal radiotherapy helps men with localized high‑risk prostate cancer stay free of metastatic disease longer.

  Recruiting at 6 sites Phase 3 Unicancer · Brest and 5 other locations · NCT06625970

• Personalizing pembrolizumab for early triple-negative breast cancer patients with a complete response

  This trial will test whether people with early triple-negative breast cancer who have a complete response after pre-surgery treatment can safely stop pembrolizumab instead of continuing it for six more months.

  Recruiting at 2 sites Phase 3 Unicancer · Brussels and 1 other locations · NCT06606730

• Ivonescimab versus FOLFOX for advanced biliary tract cancer

  This trial will test whether ivonescimab works better than standard FOLFOX chemotherapy for people with advanced biliary tract cancer after their first treatment stopped working.

  Recruiting at 17 sites Phase 2 Unicancer · Amiens and 41 other locations · NCT06529718

• Post-operative chemotherapy for high-risk uterine leiomyosarcoma patients

  This study is testing if adding four cycles of chemotherapy after surgery can help high-risk uterine leiomyosarcoma patients stay cancer-free longer compared to just regular follow-up care.

  Recruiting at 2 sites Phase 2 Unicancer · Angers and 24 other locations · NCT06524583

• Evaluating 177Lu-PSMA-617 in men with poor response to prostate cancer treatment

  This study is testing if adding a new treatment called 177Lu-PSMA-617 to standard care can help men with prostate cancer who aren’t responding well to their current treatment.

  Recruiting at 3 sites Phase 3 Unicancer · Angers and 24 other locations · NCT06496581

• Personalized chemotherapy dosing for patients with gastrointestinal cancers lacking a specific liver enzyme

  This study is testing if lowering the dose of a common chemotherapy drug can help people with gastrointestinal cancers who have a specific liver enzyme deficiency feel better while reducing side effects.

  Recruiting at 36 sites Phase 2 Unicancer · Amiens and 40 other locations · NCT06475352

• Reducing treatment for metastatic HER2-positive breast cancer with undetectable cancer levels in blood tests.

  This study is testing if patients with HER2-positive metastatic breast cancer can safely stop their treatment after two years of good results and negative blood tests showing no cancer.

  Recruiting Phase 2 Unicancer · Rennes · NCT06450314

• Dostarlimab treatment for advanced or metastatic cancers with specific genetic markers

  This study is testing if the immunotherapy dostarlimab can help people with certain advanced cancers that have specific genetic markers feel better compared to standard chemotherapy.

  Recruiting Phase 2 Unicancer · Angers and 21 other locations · NCT06333314

• Combining darolutamide with radiation therapy for advanced prostate cancer

  This study is testing if adding radiation therapy to a new hormone treatment can help men with advanced prostate cancer live longer and feel better.

  Recruiting at 4 sites Phase 3 Unicancer · Lorient and 3 other locations · NCT06276465

• Testing a new chemotherapy for patients with DPD deficiency and metastatic cancer

  This study is testing a new chemotherapy drug for people with DPD deficiency and advanced colorectal or gastroesophageal cancer to see if it is safer and more effective than standard treatments.

  Recruiting at 3 sites Phase 2 Unicancer · Amiens and 20 other locations · NCT06245356

• Treatment for early-stage triple-negative breast cancer based on tumor lymphocyte infiltration levels

  This study is testing if some patients with early-stage triple-negative breast cancer can safely skip chemotherapy based on their tumor's immune cell levels, to see if it helps them feel better without hurting their chances of recovery.

  Recruiting at 25 sites Phase 2 Unicancer · Amiens and 43 other locations · NCT06078384

• Combining capecitabine with pembrolizumab for triple negative breast cancer after surgery

  This study is testing if combining the cancer drugs capecitabine and pembrolizumab can help people with triple negative breast cancer who still have some cancer left after surgery live longer without the disease coming back.

  Recruiting at 20 sites Phase 2 Unicancer · Amiens and 19 other locations · NCT05973864

• Treatment for breast cancer patients with leptomeningeal disease

  This study is testing a new treatment combining tucatinib, capecitabine, and intrathecal trastuzumab to see if it can help people with HER2-positive metastatic breast cancer and leptomeningeal disease live longer.

  Recruiting at 10 sites Phase 2 Unicancer · Bordeaux and 10 other locations · NCT05800275

• Collecting data from patients with BRAFV600E-mutated metastatic colorectal cancer

  This study is collecting information and samples from patients with a specific type of metastatic colorectal cancer to see how well different treatments work and what factors affect their outcomes.

  Recruiting at 27 sites Unicancer · Avignon and 44 other locations · NCT05639413

• Targeted therapy for advanced biliary cancer patients

  This study is testing if a new targeted therapy can help patients with advanced biliary cancer do better after their standard treatment.

  Recruiting at 41 sites Phase 3 Unicancer · Brussels and 68 other locations · NCT05615818

• New method to monitor HPV16-related throat cancer recurrence

  This study is testing if measuring HPV16 DNA in the blood can help doctors better monitor throat cancer patients for signs of recurrence, so they can provide more personalized follow-up care.

  Recruiting at 10 sites Phase 2 Unicancer · Saint-Denis, La Réunion and 15 other locations · NCT05582122

• Monitoring targeted therapy drugs in patients with advanced digestive cancers

  This study is testing how to best monitor and adjust the doses of targeted therapy drugs for people with advanced digestive cancers to make sure they are safe and effective.

  Recruiting at 19 sites Unicancer · Amiens and 28 other locations · NCT05443087

• Shorter hormone therapy for low-risk breast cancer in postmenopausal women

  This study is testing if postmenopausal women with low-risk hormone receptor-positive breast cancer can safely take hormone therapy for just two years instead of five to see if it keeps them healthy while causing fewer side effects.

  Recruiting Phase 2 Unicancer · Limoges and 1 other locations · NCT05297617

• Evaluating ADT with or without darolutamide for prostate cancer patients with vulnerable functional ability

  This study is testing if adding darolutamide to standard hormone therapy can help men with advanced prostate cancer who have some health challenges feel better and live longer.

  Recruiting at 87 sites Phase 3 Unicancer · Charleroi and 94 other locations · NCT04916613

• Combining radiotherapy and pembrolizumab for metastatic head and neck cancers

  This study is testing if combining radiation therapy with pembrolizumab can help people with newly diagnosed metastatic head and neck cancer do better than standard treatments.

  Recruiting at 20 sites Phase 3 Unicancer · Avignon and 25 other locations · NCT04747054

• Tracking lung cancer treatment evolution in France since 2015

  This study is collecting and organizing information from lung cancer patients in France to see how their treatments have changed and what outcomes they have experienced since 2015.

  Recruiting at 21 sites Unicancer · Angers and 20 other locations · NCT03848052

• Tracking treatment evolution in metastatic breast cancer since 2008

  This study looks at how treatment for metastatic breast cancer has changed since 2008 by gathering and analyzing patient information from 18 cancer centers in France.

  Recruiting at 20 sites Unicancer · Angers and 19 other locations · NCT03275311

• Understanding chronic toxicities in localized cancer treatments

  This study is trying to understand the long-term side effects of cancer treatments in women with early-stage breast and lung cancer to see how they affect their lives and find ways to improve their quality of life.

  Recruiting Unicancer · Villejuif · NCT01993498

Quick answers

How many clinical trials run by Unicancer are recruiting right now?

38, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 15 countries. The most sites are in France (38 trials), Belgium (4 trials), Italy (4 trials), Spain (4 trials), Netherlands (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 21, Phase 3: 9, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →